2022-502952-30-00已完成1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (1)
Loading locations...
相似试验
招募中
1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)Healthy Adult ParticipantsCTIS2022-502952-30-00Janssen - Cilag International32
进行中（未招募）
1 期
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic functioActivated Phosphoinositide 3-Kinase Delta SyndromeMedDRA version: 20.0Level: PTClassification code: 10078281Term: Activated PI3 kinase delta syndrome Class: 100000004850CTIS2023-508519-22-00Pharming Technologies B.V.32
已完成
不适用
An open-label, parallel-group, single-dose study to evaluate the absolute bioavailability and tolerability of subcutaneous UCB4940 in healthy subjectspsoriasis10003816rheumatoid arthritisNL-OMON41792CB Celltech30
进行中（未招募）
不适用
Study to investigate the effect of liver impairment on the way the body eliminates the drug BAF312 in patients with mild, moderate and severe liver impairment compared to healthy persons.subjects with mild (Group 1), moderate (Group 2), and severe (Group 3) hepatic impairment.EUCTR2012-000562-37-HUovartis Pharma Services AG48
进行中（未招募）
1 期
A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2017-002060-40-Outside-EU/EEATeva Branded Pharmaceutical Products R&D, Inc.36